Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.59 |
| ▸ | HTR3A | P46098 | 2/20 | 0.59 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.59 |
| ▸ | HTR3B | O95264 | 1/20 | 0.59 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.59 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.59 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.59 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.59 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.59 |
| ▸ | HRH1 | P35367 | 1/20 | 0.59 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.59 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.59 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.59 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.59 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | ALPL | P05186 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6887665 | 0.85 | CHRNA7 (0.66) | SIGMAR1HTR3AHTR3EHTR3BCHRM4 | |
| SCHEMBL2191318 | 0.83 | HTR3E (0.63) | SIGMAR1HTR3AHTR3EHTR3BCHRM4 | |
| SCHEMBL6886781 | 0.83 | HTR3E (0.63) | SIGMAR1HTR3AHTR3EHTR3BCHRM4 | |
| SCHEMBL6886806 | 0.82 | SIGMAR1 (0.65) | SIGMAR1HTR3AHTR3EHTR3BCHRM4 | |
| SCHEMBL6885989 | 0.80 | SIGMAR1 (0.72) | SIGMAR1HTR3AHTR3EHTR3BCHRM4 | |
| SCHEMBL19223474 | 0.77 | SLC6A3 (0.53) | SLC6A3LTA4HPOLBGBA1UGCG | |
| Bromide SCHEMBL4001835 | 0.76 | SLC6A3 (0.54) | SLC6A3LTA4HPOLBGBA1UGCG | |
| SCHEMBL6886650 | 0.76 | HTR3E (0.67) | SIGMAR1HTR3AHTR3EHTR3BCHRM4 | |
| SCHEMBL2190458 | 0.75 | SIGMAR1 (0.62) | SIGMAR1HTR3AHTR3EHTR3BCHRM4 | |
| SCHEMBL6886979 | 0.75 | SIGMAR1 (0.62) | SIGMAR1HTR3AHTR3EHTR3BCHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170224665-A1 | SELECTIVE HIGH AFFINITY ALFA3BETA4 NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | Astraea Therapeutics (US) | 2017-08-10 | — | — | US | disclosed |
| US-20170224665-A1 | SELECTIVE HIGH AFFINITY ALFA3BETA4 NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | Astraea Therapeutics (US) | 2017-08-10 | — | — | US | disclosed |
| US-9670198-B2 | Nicotinic acetylcholine receptor modulators | ASTRAEA THERAPEUTICS, LLC (US) | 2017-06-06 | — | — | US | disclosed |
| US-9670198-B2 | Nicotinic acetylcholine receptor modulators | ASTRAEA THERAPEUTICS, LLC (US) | 2017-06-06 | — | — | US | disclosed |
| US-9062042-B2 | Nicotinic acetylcholine receptor modulators | ASTRAEA THERAPEUTICS, LLC (US) | 2015-06-23 | — | — | US | disclosed |
| US-9062042-B2 | Nicotinic acetylcholine receptor modulators | ASTRAEA THERAPEUTICS, LLC (US) | 2015-06-23 | — | — | US | disclosed |
| US-20150148541-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | Astraea Therapeutics (US) | 2015-05-28 | — | — | US | disclosed |
| US-20150148541-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | Astraea Therapeutics (US) | 2015-05-28 | — | — | US | disclosed |
| US-20110172264-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | ASTRAEA THERAPEUTICS, LLC | 2011-07-14 | — | — | US | disclosed |
| US-20110172264-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | ASTRAEA THERAPEUTICS, LLC | 2011-07-14 | — | — | US | disclosed |
| WO-2011085389-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | ASTRAEA THERAPEUTICS, LLC (US) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172264-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | CHRNA4, CHRNA3, CHRNA6 | SIGMAR1 76/4885HTR3A 51/4885HTR3E 139/4885 |
| US-20170224665-A1 | SELECTIVE HIGH AFFINITY ALFA3BETA4 NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | CHRNA3, CHRNA4, CHRNB3 | SIGMAR1 35/4885HTR3A 65/4885HTR3E 181/4885 |
| US-20150148541-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | CHRNA3, CHRNA4, CHRNA2 | SIGMAR1 60/4885HTR3A 68/4885HTR3E 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.